Search results for "Transfusion"

showing 10 items of 177 documents

Totally laparoscopic liver resections for primary and metastatic cancer in the elderly: safety, feasibility and short-term outcomes.

2012

Standard oncologic liver resections performed on elderly patients (≥70 years old) have been shown to be safe and effective. The aim of this study was to analyze operative and oncologic short-term outcomes of totally laparoscopic liver resections (TLLR) performed on elderly patients for malignancies. We performed a retrospective statistical analysis of prospectively recorded data of TLLR performed from October 2008 to February 2012 by a single hepato-pancreato-biliary (HPB) surgeon. Patients were divided into two groups according to age (<70 vs. ≥70 years old) and perioperative outcomes were compared. A total of 60 TLLR for malignancies were identified of which 25 patients (42 %) were aged ≥…

AdultMalemedicine.medical_specialtyBlood transfusionCarcinoma HepatocellularCritical Caremedicine.medical_treatmentOperative TimePostoperative ComplicationsmedicineHepatectomyHumansLiver neoplasmProspective StudiesProspective cohort studyAgedRetrospective StudiesAged 80 and overbusiness.industryMortality rateLiver NeoplasmsRetrospective cohort studyPerioperativeLength of StayMiddle AgedLAPAROSCOPIC LIVER RESECTIONS METASTATIC CANCERSurgeryTreatment OutcomeSurgeryFemaleLaparoscopyHepatectomyNeoplasm Recurrence LocalbusinessAbdominal surgerySurgical endoscopy
researchProduct

Prognostic factors for cryotherapy of colorectal liver metastases.

2004

Abstract Background . Cryotherapy is a local ablative treatment option for non-resectable liver tumours. We aimed to identify prognostic indicators, that may allow better selection or stratification for adjuvant therapies of patients. Methods . Fifty-five patients had cryotherapy for colorectal liver metastases. The patient-, tumour- and operative details were recorded prospectively. Mean follow up was 24 months. A uni- and multivariate analysis for possible prognostic factors was performed. Results . There was a trend towards better survival for patients with unilobar liver metastases, preoperative serum levels of carcinoembrional antigen (CEA) not exceeding 20 ng/ml and patients undergoin…

AdultMalemedicine.medical_specialtyBlood transfusionMultivariate analysisColorectal cancermedicine.medical_treatmentCryotherapyGastroenterologyCryosurgeryCryosurgeryInternal medicinemedicineHumansAgedUnivariate analysisbusiness.industryProportional hazards modelLiver NeoplasmsGeneral MedicineMiddle Agedmedicine.diseasePrognosisSurgeryCarcinoembryonic AntigenSurvival RateOncologySurgeryFemalebusinessColorectal NeoplasmsAdjuvantBiomarkersEuropean journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
researchProduct

Anastomotic leakage after colon cancer resection: does the individual surgeon matter?

2016

Aim Anastomotic leakage is one of the most feared complications after colonic resection. Many risk factors for anastomotic leakage have been reported, but the impact of an individual surgeon as a risk factor has scarcely been reported. The aim of this study was to assess if the individual surgeon is an independent risk factor for anastomotic leakage in colonic cancer surgery. Method This was a retrospective analysis of prospectively collected data from patients who underwent elective resection for colon cancer with anastomosis at a specialized colorectal unit from January 1993 to December 2010. Anastomotic leaks were diagnosed according to standardized criteria. Patient and tumour character…

AdultMalemedicine.medical_specialtyBlood transfusionindividual surgeonColonColorectal cancermedicine.medical_treatmentAnastomotic Leak030230 surgeryAnastomosis03 medical and health sciences0302 clinical medicineIleorectal anastomosisRisk FactorsTask Performance and AnalysisColon cancer resectionHumansAnastomotic leakMedicineBlood TransfusionRisk factorcolon resectionColectomyAgedRetrospective StudiesAged 80 and overbusiness.industryAnastomosis SurgicalGastroenterologyPerioperativeMiddle Agedmedicine.diseaseSurgeryrisk factorcolon cancerElective Surgical ProceduresAnastomotic leakage030220 oncology & carcinogenesisColonic NeoplasmsFemaleClinical CompetencebusinessColorectal Disease
researchProduct

Liver transplantation for hepatocellular carcinoma--is there a risk of recurrence caused by intraoperative blood salvage autotransfusion?

2011

&lt;i&gt;Background/Aims:&lt;/i&gt; The use of intraoperative blood salvage autotransfusion (IBSA) during surgical approaches may contribute to tumour cell dissemination. Therefore, IBSA should be avoided in cases of malignancy. However, the risks of IBSA might be acceptable in liver transplantation (LT) for selected small hepatocellular carcinoma (HCC). &lt;i&gt;Methods:&lt;/i&gt; In total, 136 recipients of LT with histologically proven HCC in the explanted liver were included in this analysis. With regard to tumour recurrence, 40 patients receiving IBSA despite HCC (IBSA group) were compared to 96 patients without IBSA (non-IBSA group). &lt;i&gt;Results:&lt;/i&gt; Milan criteria as asses…

AdultMalemedicine.medical_specialtyCarcinoma Hepatocellularmedicine.medical_treatmentLiver transplantationMilan criteriaNeoplasm RecurrenceRisk FactorsmedicineCarcinomaHumansAgedSurgical approachIntraoperative blood salvagebusiness.industryOperative Blood SalvageLiver NeoplasmsMiddle Agedmedicine.diseaseNeoplastic Cells CirculatingSurgeryLiver TransplantationHepatocellular carcinomaSurgeryFemaleRadiologyNeoplasm Recurrence LocalbusinessAutotransfusionEuropean surgical research. Europaische chirurgische Forschung. Recherches chirurgicales europeennes
researchProduct

Transfusion-associated chronic hepatitis C: alpha-n1 interferon for 6 vs. 12 months.

1996

Abstract Aims: To compare the long-term effects of brief and prolonged therapy with alpha-n 1 interferon for transfusion-associated chronic hepatitis C. Methods: One hundred and sixteen subjects (male/female 4868, mean age 46.9 years) were studied. Sixty patients were randomised to brief treatment (group 1: interferon 5 Mu/msq. t.i.w. for 2 months, then 3 Mu/msq. t.i.w. for 4 months), and 56 to prolonged treatment (group 2: interferon 5 Mu/msq. t.i.w. for 2 months, then 3 Mu/msq. t.i.w. for 10 months). All were followed for 12 months after stopping interferon. Results: The early response rate was 47.4% (Group 1 [45%], Group 2 [50%]). No "breakthrough" reactivations were observed. The early …

AdultMalemedicine.medical_specialtyCirrhosisAdolescentmedicine.medical_treatmentHepatitis C virusPopulationAlpha interferonmedicine.disease_causeGastroenterologyAntibodiesDrug Administration ScheduleInterferonInternal medicinemedicineHumanseducationInterferon alfaAgededucation.field_of_studyHepatologybusiness.industryInterferon-alphaTransfusion ReactionImmunotherapyMiddle Agedmedicine.diseaseHepatitis CSurgeryChronic DiseaseFemalebusinessComplicationmedicine.drugJournal of hepatology
researchProduct

Deferiprone versus Deferoxamine in Sickle Cell Disease: Results from a 5-year long-term Italian multi-center randomized clinical trial

2014

Blood transfusion and iron chelation currently represent a supportive therapy to manage anemia, vasculopathy and vaso-occlusion crises in Sickle-Cell-Disease. Here we describe the first 5-year long-term randomized clinical trial comparing Deferiprone versus Deferoxamine in patients with Sickle-Cell-Disease. The results of this study show that Deferiprone has the same effectiveness as Deferoxamine in decreasing body iron burden, measured as repeated measurements of serum ferritin concentrations on the same patient over 5-years and analyzed according to the linear mixed-effects model (LMM) (p=0.822). Both chelators are able to decrease, significantly, serum ferritin concentrations, during 5-y…

AdultMalemedicine.medical_specialtyIron OverloadBlood transfusionAdolescentPyridonesAnemiaIronmedicine.medical_treatmentAnemia Sickle CellDeferoxamineIron Chelating AgentsGastroenterologylaw.inventionchemistry.chemical_compoundBasal (phylogenetics)Randomized controlled triallawInternal medicineHumansMedicineBlood TransfusionDeferiproneChildMolecular Biologybusiness.industryCell BiologyHematologyMiddle Agedmedicine.diseaseSurvival AnalysisSurgeryDeferoxamineItalychemistrySupportive psychotherapyFerritinsCohortLinear ModelsMolecular MedicineFemalebusinessDeferipronemedicine.drugBlood Cells, Molecules, and Diseases
researchProduct

Phase IV open-label study of the efficacy and safety of deferasirox after allogeneic stem cell transplantation

2014

This is the first prospective study of deferasirox in adult allogeneic hematopoietic stem cell transplant recipients with transfusional iron overload in hematologic malignancies. Patients at least six months post transplant were treated with deferasirox at a starting dose of 10 mg/kg/day for 52 weeks or until serum ferritin was less than 400 ng/mL on two consecutive occasions. Thirty patients were enrolled and 22 completed the study. A significant reduction from baseline in median serum ferritin and in liver iron concentration at 52 weeks was observed in the overall population: from 1440 to 755.5 ng/mL (P=0.002) and from 14.5 to 4.6 mg Fe/g dw (P=0.0007), respectively. Reduction in serum fe…

AdultMalemedicine.medical_specialtyLiver Iron ConcentrationIron Overloadmedicine.medical_treatmentPopulationStem cellsHematopoietic stem cell transplantationIron Chelating AgentsBenzoatesGastroenterologyYoung Adultchemistry.chemical_compoundInternal medicinemedicineHumansTransplantation HomologousAdverse effecteducationProspective cohort studyAgededucation.field_of_studyCreatininebusiness.industryDeferasiroxHematopoietic Stem Cell TransplantationHematologic diseasesTransfusion ReactionArticlesHematologyMiddle AgedTriazolesSurgeryTransplantationDeferasiroxTreatment OutcomechemistryMalalties hematològiquesFerritinsFemaleCèl·lules marebusinessmedicine.drug
researchProduct

Magnetic resonance imaging of the pituitary gland in patients with secondary hypogonadism due to transfusional hemochromatosis

1999

To identify pituitary iron overload in patients with transfusional hemochromatosis causing secondary hypogonadism, we prospectively evaluated signal intensity abnormalities of the anterior lobe of the pituitary gland of 18 patients affected by transfusion-dependent thalassemia major and secondary hypogonadism. Magnetic resonance (MR) imaging is useful to assess pituitary iron overload in patients with transfusional hemochromatosis and secondary hypogonadism by detection of a significant decreased signal intensity of the anterior lobe of the pituitary gland on GRE T2*-weighted images. The decreased signal intensity of the anterior lobe of the pituitary gland on GRE T2*-weighted images was co…

AdultMalemedicine.medical_specialtyPathologyPituitary glandAdolescentThalassemiaBiophysicsPituitary InsufficiencyInternal medicinemedicineHumansRadiology Nuclear Medicine and imagingIn patientHemochromatosisRadiological and Ultrasound Technologymedicine.diagnostic_testbusiness.industryHypogonadismSerum ferritin levelTransfusion ReactionPterygoid MusclesMagnetic resonance imagingmedicine.diseaseMagnetic Resonance ImagingEndocrinologymedicine.anatomical_structurePituitary GlandFerritinsThalassemiaFemaleHemochromatosisbusinessHormoneMagma: Magnetic Resonance Materials in Physics, Biology, and Medicine
researchProduct

Posttransfusional, LKM-1-autoantibody-positive hepatitis C virus infection, cryoglobulinemia, and aplastic anemia.

1995

Aplastic anemia is occasionally caused by viral hepatitis, hepatitis C virus being the most important factor. Pathogenetically, decreased bone marrow function, abnormalities of the bone marrow microenvironment, and immune-mediated suppression of hematopoiesis are important. Hepatitis C virus infection is associated with a variety of extrahepatic manifestations including autoimmune features like cryoglobulinemia, Sjogren's syndrome, and autoimmune hepatitis. Here we report the case of a 42-year-old man with aplastic anemia due to posttransfusional hepatitis C virus infection associated with cryoglobulinemia and LKM-1 autoantibodies. Following a triple immunosuppressive therapy, there was a c…

AdultMalemedicine.medical_specialtyPhysiologyHepatitis C virusAutoimmune hepatitismedicine.disease_causeBone MarrowInternal medicinemedicineHumansAplastic anemiaAutoantibodiesbusiness.industryGastroenterologyAutoantibodyAnemia AplasticTransfusion ReactionHepatologymedicine.diseaseVirologyCryoglobulinemiaHepatitis Cmedicine.anatomical_structureCryoglobulinemiaImmunologyBone marrowbusinessViral hepatitisDigestive diseases and sciences
researchProduct

Transfusion-dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelof…

2010

The International Prognostic Scoring System (IPSS) and karyotype are useful tools for risk stratification in primary myelofibrosis (PMF). We examined the additional prognostic impact of red blood cell transfusion need among 254 consecutive patients (median age, 59 years). Sixty-two patients ( approximately 24%) required transfusions at diagnosis whereas 22 ( approximately 9%) became transfusion-dependent and 170 remained transfusion-independent during the first year postdiagnosis; after a median follow-up of 55 months, the respective median survivals were 35, 25, and 117 months (P < 0.01). Multivariable analysis confirmed the IPSS- and karyotype-independent prognostic weight of transfusion …

AdultMalemedicine.medical_specialtytransfusion myelofibrosisPROGNOSISmedicine.medical_treatmentmyelofibrosisHematopoietic stem cell transplantationSeverity of Illness IndexSettore MED/15 - Malattie Del SangueRisk FactorsInternal medicineSeverity of illnessmedicineHumansMyelofibrosisSurvival analysisAgedRetrospective StudiesAged 80 and overChromosome AberrationsHematologybusiness.industryPatient SelectionMyelodysplastic syndromesHematopoietic Stem Cell TransplantationRetrospective cohort studyHematologyMiddle Agedmedicine.diseaseSurvival AnalysisSurgeryPrimary MyelofibrosisInternational Prognostic Scoring SystemRBC transfusiion; myelofibrosis; PROGNOSISFemaleErythrocyte TransfusionbusinessFollow-Up StudiesRBC transfusiionAmerican Journal of Hematology
researchProduct